Barry V L Potter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9580154/publications.pdf

Version: 2024-02-01

225 papers	8,654 citations	38720 50 h-index	64755 79 g-index
229 all docs	229 docs citations	229 times ranked	5863 citing authors

#	Article	IF	Citations
1	A structural exposÃ© of noncanonical molecular reactivity within the protein tyrosine phosphatase WPD loop. Nature Communications, 2022, 13, 2231.	5.8	7
2	Cell Fate following Irradiation of MDA-MB-231 and MCF-7 Breast Cancer Cells Pre-Exposed to the Tetrahydroisoquinoline Sulfamate Microtubule Disruptor STX3451. Molecules, 2022, 27, 3819.	1.7	1
3	Nâ€Phenylâ€1,2,3,4â€tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17Î²â€Hydroxysteroid Dehydrogenase 1 Inhibitors. ChemMedChem, 2021, 16, 259-291.	1.6	4
4	Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. Journal of Medicinal Chemistry, 2021, 64, 3813-3826.	2.9	5
5	Multiple substrate recognition by yeast diadenosine and diphosphoinositol polyphosphate phosphohydrolase through phosphate clamping. Science Advances, 2021, 7, .	4.7	12
6	2-Methoxyestradiol and its derivatives inhibit store-operated Ca2+ entry in T cells: Identification of a new and potent inhibitor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118988.	1.9	6
7	Quantal Ca2+ release mediated by very few IP3 receptors that rapidly inactivate allows graded responses to IP3. Cell Reports, 2021, 37, 109932.	2.9	7
8	Small Molecule CD38 Inhibitors: Synthesis of 8-Amino-N1-inosine 5â€²-monophosphate, Analogues and Early Structure-Activity Relationship. Molecules, 2021, 26, 7165.	1.7	0
9	Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17Î²-Hydroxysteroid Dehydrogenase Type 3. Molecules, 2021, 26, 7166.	1.7	1
10	Regioisomeric Family of Novel Fluorescent Substrates for SHIP2. ACS Medicinal Chemistry Letters, 2020, 11, 309-315.	1.3	1
11	The inositol pyrophosphate 5-InsP ₇ drives sodium-potassium pump degradation by relieving an autoinhibitory domain of PI3K p85Î±. Science Advances, 2020, 6, .	4.7	16
12	Inositol Adenophostin: Convergent Synthesis of a Potent Agonist of <scp>d</scp>-myo-Inositol 1,4,5-Trisphosphate Receptors. ACS Omega, 2020, 5, 28793-28811.	1.6	5
13	Rapid and Efficient Microwaveâ€Assisted FriedlÃnder Quinoline Synthesis. ChemistryOpen, 2020, 9, 1113-1122.	0.9	6
14	A new series of aryl sulfamate derivatives: Design, synthesis, and biological evaluation. Bioorganic and Medicinal Chemistry, 2020, 28, 115406.	1.4	16
15	<scp>d</scp>-chiro-Inositol Ribophostin: A Highly Potent Agonist of <scp>d</scp>-myo-Inositol 1,4,5-Trisphosphate Receptors: Synthesis and Biological Activities. Journal of Medicinal Chemistry, 2020, 63, 3238-3251.	2.9	11
16	Synthesis of phosphonoacetate analogues of the second messenger adenosine 5â€²-diphosphate ribose (ADPR). RSC Advances, 2020, 10, 1776-1785.	1.7	6
17	Both <scp>d</scp>- and <scp>l</scp>-Glucose Polyphosphates Mimic <scp>d</scp>-myo-Inositol 1,4,5-Trisphosphate: New Synthetic Agonists and Partial Agonists at the Ins(1,4,5)P₃ Receptor. Journal of Medicinal Chemistry, 2020, 63, 5442-5457.	2.9	8
18	An ATP-responsive metabolic cassette comprised of inositol tris/tetrakisphosphate kinase 1 (ITPK1) and inositol pentakisphosphate 2-kinase (IPK1) buffers diphosphoinositol phosphate levels. Biochemical Journal, 2020, 477, 2621-2638.	1.7	40

#	Article	IF	Citations
19	Synthesis and inÂvitro evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111614.	2.6	11
20	Steroid Sulfatase Inhibition: From Concept to Clinic and Beyond. Proceedings (mdpi), 2019, 22, 25.	0.2	0
21	Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2). BMC Pharmacology & Toxicology, 2019, 20, 67.	1.0	3
22	Synthesis of an Î±-phosphono-Î±,Î±-difluoroacetamide analogue of the diphosphoinositol pentakisphosphate 5-InsP₇. MedChemComm, 2019, 10, 1165-1172.	3.5	10
23	A synthetic cyclitol-nucleoside conjugate polyphosphate is a highly potent second messenger mimic. Chemical Science, 2019, 10, 5382-5390.	3.7	11
24	Different substrate specificities of the two ADPR binding sites in TRPM2 channels of Nematostella vectensis and the role of IDPR. Scientific Reports, 2019, 9, 4985.	1.6	14
25	Synthesis of Terminal Ribose Analogues of Adenosine 5â€²-Diphosphate Ribose as Probes for the Transient Receptor Potential Cation Channel TRPM2. Journal of Organic Chemistry, 2019, 84, 6143-6157.	1.7	14
26	3,17Î²-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structureâ€“Activity Optimization for Isoform Selectivity. Journal of Medicinal Chemistry, 2019, 62, 2202-2212.	2.9	14
27	Inositol hexakisphosphate increases the size of platelet aggregates. Biochemical Pharmacology, 2019, 161, 14-25.	2.0	8
28	Tetrahydroisoquinoline Sulfamates as Potent Microtubule Disruptors: Synthesis, Antiproliferative and Antitubulin Activity of Dichlorobenzyl-Based Derivatives, and a Tubulin Cocrystal Structure. ACS Omega, 2019, 4, 755-764.	1.6	9
29	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. Journal of Molecular Endocrinology, 2018, 61, T233-T252.	1.1	55
30	Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure. Journal of Medicinal Chemistry, 2018, 61, 1031-1044.	2.9	91
31	Simple synthesis of 32P-labelled inositol hexakisphosphates for study of phosphate transformations. Plant and Soil, 2018, 427, 149-161.	1.8	8
32	Small Molecule Antagonists of NAADP-Induced Ca2+ Release in T-Lymphocytes Suggest Potential Therapeutic Agents for Autoimmune Disease. Scientific Reports, 2018, 8, 16775.	1.6	7
33	Synthetic cADPR analogues may form only one of two possible conformational diastereoisomers. Scientific Reports, 2018, 8, 15268.	1.6	3
34	C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors. ACS Omega, 2018, 3, 10748-10772.	1.6	21
35	A Fluorescent Probe Identifies Active Site Ligands of Inositol Pentakisphosphate 2-Kinase. Journal of Medicinal Chemistry, 2018, 61, 8838-8846.	2.9	6
36	Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 breast and A549 lung cancer cell lines. Drug Design, Development and Therapy, 2018, Volume 12, 1881-1904.	2.0	7

#	Article	IF	Citations
37	A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate. MedChemComm, 2018, 9, 1105-1113.	3.5	7
38	SHIP2: Structure, Function and Inhibition. ChemBioChem, 2017, 18, 233-247.	1.3	35
39	Ligand-induced activation of human TRPM2 requires the terminal ribose of ADPR and involves Arg1433 and Tyr1349. Biochemical Journal, 2017, 474, 2159-2175.	1.7	31
40	Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6381-E6389.	3.3	46
41	2â€²-Deoxyadenosine 5â€²-diphosphoribose is an endogenous TRPM2 superagonist. Nature Chemical Biology, 2017, 13, 1036-1044.	3.9	66
42	Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid â€œL-cyclic inosine 5â€²-diphosphate riboseâ€• Scientific Reports, 2017, 7, 16100.	1.6	4
43	Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranzâ€“Fritschâ€“Bobbitt reaction with non-activated and moderately-activated systems. Beilstein Journal of Organic Chemistry, 2017, 13, 1871-1878.	1.3	8
44	Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nature Communications, 2016, 7, 11262.	5.8	172
45	Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 2762-2767.	1.4	27
46	A Small Molecule Inhibitor of PDK1/PLCÎ³1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion. Scientific Reports, 2016, 6, 26142.	1.6	26
47	Die â€œanderenâ€•Inositole und ihre Phosphate: Synthese, Biologie und Medizin (sowie jÃ¼ngste) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	3
48	The â€œOtherâ€•Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in) Tj ETQq0 0 0 rgBT /Overloc	7.2	141
49	Crystal Structures of Type-II Inositol Polyphosphate 5-Phosphatase INPP5B with Synthetic Inositol Polyphosphate Surrogates Reveal New Mechanistic Insights for the Inositol 5-Phosphatase Family. Biochemistry, 2016, 55, 1384-1397.	1.2	12
50	Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol. British Journal of Cancer, 2015, 113, 1158-1167.	2.9	10
51	Calcium Signalling Triggered by NAADP in T Cells Determines Cell Shape and Motility During Immune Synapse Formation. Messenger (Los Angeles, Calif: Print), 2015, 4, 104-111.	0.3	7
52	Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Womenâ€™s Health. Journal of Medicinal Chemistry, 2015, 58, 7634-7658.	2.9	72
53	Designer small molecules to target calcium signalling. Biochemical Society Transactions, 2015, 43, 417-425.	1.6	8
54	Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential. Journal of Steroid Biochemistry and Molecular Biology, 2015, 153, 160-169.	1.2	37

#	Article	IF	Citations
55	Synthetic tools for studying the chemical biology of InsP₈. Chemical Communications, 2015, 51, 12605-12608.	2.2	18
56	The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. Anticancer Research, 2015, 35, 5249-61.	0.5	8
57	Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose. Messenger (Los Angeles, Calif: Print), 2014, 3, 35-51.	0.3	3
58	Cyclic Adenosine 5â€²-Diphosphate Ribose Analogs without a â€œSouthernâ€•Ribose Inhibit ADP-ribosyl Cyclaseâ€“Hydrolase CD38. Journal of Medicinal Chemistry, 2014, 57, 8517-8529.	2.9	19
59	Human Genome-Wide RNAi Screen Identifies an Essential Role for Inositol Pyrophosphates in Type-I Interferon Response. PLoS Pathogens, 2014, 10, e1003981.	2.1	68
60	The enzymes of human diphosphoinositol polyphosphate metabolism. FEBS Journal, 2014, 281, 14-33.	2.2	49
61	Optimisation of Tetrahydroisoquinolineâ€Based Chimeric Microtubule Disruptors. ChemMedChem, 2014, 9, 1783-1793.	1.6	14
62	Synthesis, Anti-tubulin and Antiproliferative SAR of Steroidomimetic Dihydroisoquinolinones. ChemMedChem, 2014, 9, 798-812.	1.6	15
63	Synthesis, Antitubulin, and Antiproliferative SAR of C3/C1â€Substituted Tetrahydroisoquinolines. ChemMedChem, 2014, 9, 350-370.	1.6	17
64	Tetrahydroisoquinolinoneâ€Based Steroidomimetic and Chimeric Microtubule Disruptors. ChemMedChem, 2014, 9, 85-108.	1.6	16
65	Cellular Internalisation of an Inositol Phosphate Visualised by Using Fluorescent InsP₅. ChemBioChem, 2014, 15, 57-67.	1.3	16
66	â€˜Click cyclic ADP-riboseâ€™: a neutral second messenger mimic. Chemical Communications, 2014, 50, 2458-2461.	2.2	25
67	Synthetic Inositol Phosphate Analogs Reveal that PPIP5K2 Has a Surface-Mounted Substrate Capture Site that Is a Target for Drug Discovery. Chemistry and Biology, 2014, 21, 689-699.	6.2	56
68	The structural biology of oestrogen metabolism. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 27-49.	1.2	129
69	Inframolecular acidâ€“base and coordination properties towards Na⁺and Mg²⁺of myo-inositol 1,3,4,5,6-pentakisphosphate: a structural approach to biologically relevant species. Dalton Transactions, 2013, 42, 6021-6032.	1.6	9
70	Synthesis and Structureâ€“Activity Relationship Studies of Derivatives of the Dual Aromataseâ€“Sulfatase Inhibitor 4â€{[(4â€Cyanophenyl)(4Hâ€1,2,4â€triazolâ€4â€yl)amino]methyl}phenyl sulfamate. ChemMedChem, 2013, 8, 779-799.	1.6	26
71	Structureâ€“Activity Relationship of Adenosine 5â€²-diphosphoribose at the Transient Receptor Potential Melastatin 2 (TRPM2) Channel: Rational Design of Antagonists. Journal of Medicinal Chemistry, 2013, 56, 10079-10102.	2.9	63
72	Regioselective Opening of myo-Inositol Orthoesters: Mechanism and Synthetic Utility. Journal of Organic Chemistry, 2013, 78, 2275-2288.	1.7	14

#	Article	IF	Citations
73	STX2171, a 17Î²-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine-Related Cancer, 2013, 20, 53-64.	1.6	17
74	Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling and Arrhythmias in the Heart Evoked by Î²-Adrenergic Stimulation. Journal of Biological Chemistry, 2013, 288, 16017-16030.	1.6	41
75	Stimulation of Inositol 1,4,5-Trisphosphate (IP3) Receptor Subtypes by Analogues of IP3. PLoS ONE, 2013, 8, e54877.	1.1	22
76	Stimulation of Inositol 1,4,5-Trisphosphate (IP3) Receptor Subtypes by Adenophostin A and Its Analogues. PLoS ONE, 2013, 8, e58027.	1.1	16
77	CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5â€²-Diphosphate Ribose Template. PLoS ONE, 2013, 8, e66247.	1.1	24
78	Multivalent Benzene Polyphosphate Derivatives are Non-Ca²⁺-Mobilizing Ins(1,4,5)P₃ Receptor Antagonists. Messenger (Los Angeles, Calif: Print), 2012, 1, 167-181.	0.3	11
79	First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase. Chemical Communications, 2012, 48, 11292.	2.2	30
80	Total Synthesis of a Cyclic Adenosine 5â€²-Diphosphate Ribose Receptor Agonist. Journal of Organic Chemistry, 2012, 77, 4191-4197.	1.7	23
81	Aberrant Cyclization Affords a C-6 Modified Cyclic Adenosine 5â€²-Diphosphoribose Analogue with Biological Activity in Jurkat T Cells. Journal of Medicinal Chemistry, 2012, 55, 1478-1489.	2.9	22
82	Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors. ACS Medicinal Chemistry Letters, 2012, 3, 5-9.	1.3	28
83	A Synthetic Polyphosphoinositide Headgroup Surrogate in Complex with SHIP2 Provides a Rationale for Drug Discovery. ACS Chemical Biology, 2012, 7, 822-828.	1.6	35
84	Contribution of Phosphates and Adenine to the Potency of Adenophostins at the IP₃ Receptor: Synthesis of All Possible Bisphosphates of Adenophostin A. Journal of Medicinal Chemistry, 2012, 55, 1706-1720.	2.9	22
85	Synthesis and evaluation of thiadiazole derivatives as inhibitors of 11Î²-hydroxysteroid dehydrogenase type 1. MedChemComm, 2012, 3, 1117.	3.5	6
86	Determination of neo- and <scp>d</scp>-chiro-Inositol Hexakisphosphate in Soils by Solution ³¹P NMR Spectroscopy. Environmental Science & Technology, 2012, 46, 4994-5002.	4.6	119
87	Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 2506-2519.	1.4	43
88	Development of steroid sulfatase inhibitors. Molecular and Cellular Endocrinology, 2011, 340, 175-185.	1.6	53
89	Synthesis of cyclic adenosine 5â€²-diphosphate ribose analogues: a C2â€² endo/syn â€œsouthernâ€•ribose conformation underlies activity at the sea urchin cADPR receptor. Organic and Biomolecular Chemistry, 2011, 9, 278-290.	1.5	23
90	Structureâ€“Activity Relationships of C-17-Substituted Estratriene-3-O-sulfamates as Anticancer Agents. Journal of Medicinal Chemistry, 2011, 54, 4863-4879.	2.9	21

#	Article	IF	Citations
91	Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity. ACS Medicinal Chemistry Letters, 2011, 2, 243-247.	1.3	34
92	Structureâ€“Activity Relationship for the Firstâ€inâ€Class Clinical Steroid Sulfatase Inhibitor Irosustat (STX64, BN83495). ChemMedChem, 2011, 6, 2019-2034.	1.6	57
93	Chimeric microtubule disruptors. Chemical Communications, 2010, 46, 2907.	2.2	26
94	Highly Potent First Examples of Dual Aromataseâ˜Steroid Sulfatase Inhibitors based on a Biphenyl Template. Journal of Medicinal Chemistry, 2010, 53, 2155-2170.	2.9	76
95	Binding of Inositol 1,4,5-trisphosphate (IP₃) and Adenophostin A to the N-Terminal region of the IP₃Receptor: Thermodynamic Analysis Using Fluorescence Polarization with a Novel IP₃Receptor Ligand. Molecular Pharmacology, 2010, 77, 995-1004.	1.0	37
96	Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain, 2010, 133, 1930-1943.	3.7	59
97	Synthesis, Antitubulin, and Antiproliferative SAR of Analogues of 2-Methoxyestradiol-3,17-O,O-bis-sulfamate. Journal of Medicinal Chemistry, 2010, 53, 2942-2951.	2.9	39
98	Structures of Human Carbonic Anhydrase II/Inhibitor Complexes Reveal a Second Binding Site for Steroidal and Nonsteroidal Inhibitors[,]. Biochemistry, 2010, 49, 3464-3476.	1.2	18
99	Adenophostins. Current Topics in Membranes, 2010, 66, 209-233.	0.5	25
100	NAADP-mediated Ca ²⁺ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10678-10683.	3.3	100
101	Structural Basis for Enzymatic Evolution from a Dedicated ADP-ribosyl Cyclase to a Multifunctional NAD Hydrolase. Journal of Biological Chemistry, 2009, 284, 27637-27645.	1.6	53
102	Synthetic partial agonists reveal key steps in IP3 receptor activation. Nature Chemical Biology, 2009, 5, 631-639.	3.9	69
103	The Development of Steroid Sulfatase Inhibitors for Hormoneâ€Dependent Cancer Therapy. Annals of the New York Academy of Sciences, 2009, 1155, 80-87.	1.8	37
104	The design of novel 17Î²-hydroxysteroid dehydrogenase type 3 inhibitors. Molecular and Cellular Endocrinology, 2009, 301, 259-265.	1.6	26
105	Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17Î²-hydroxysteroid dehydrogenase Type 3. Molecular and Cellular Endocrinology, 2009, 301, 251-258.	1.6	16
106	Activation of IP3 receptors by synthetic bisphosphate ligands. Chemical Communications, 2009, , 1204.	2.2	27
107	8-Bromo-cyclic inosine diphosphoribose: towards a selective cyclic ADP-ribose agonist. Biochemical Journal, 2009, 422, 139-149.	1.7	20
108	Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Research and Treatment, 2008, 111, 129-138.	1.1	34

#	Article	IF	Citations
109	2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel exÂvivo technique. Breast Cancer Research and Treatment, 2008, 111, 251-260.	1.1	29
110	Direct Evidence for ArOï£¿S Bond Cleavage upon Inactivation of Pseudomonas aeruginosa Arylsulfatase by Aryl Sulfamates. ChemBioChem, 2008, 9, 613-623.	1.3	29
111	Benzene Polyphosphates as Tools for Cell Signalling: Inhibition of Inositol 1,4,5â€Trisphosphate 5â€Phosphatase and Interaction with the PH Domain of Protein Kinase BÎ±. ChemBioChem, 2008, 9, 1757-1766.	1.3	17
112	17Î²â€hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormoneâ€dependent breast cancer. International Journal of Cancer, 2008, 122, 1931-1940.	2.3	99
113	Novel inhibitors of 17Î²-hydroxysteroid dehydrogenase type 1: Templates for design. Bioorganic and Medicinal Chemistry, 2008, 16, 4438-4456.	1.4	36
114	Chiral Aromatase and Dual Aromataseâ^'Steroid Sulfatase Inhibitors from the Letrozole Template: Synthesis, Absolute Configuration, and In Vitro Activity. Journal of Medicinal Chemistry, 2008, 51, 4226-4238.	2.9	80
115	Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modelling. Organic and Biomolecular Chemistry, 2008, 6, 4108.	1.5	31
116	2-Position Base-Modified Analogues of Adenophostin A as High-Affinity Agonists of the d-myo-Inositol Trisphosphate Receptor:â€‰ In Vitro Evaluation and Molecular Modeling. Journal of Organic Chemistry, 2008, 73, 1682-1692.	1.7	19
117	2â€²-Deoxy Cyclic Adenosine 5â€²-Diphosphate Ribose Derivatives: Importance of the 2â€²-Hydroxyl Motif for the Antagonistic Activity of 8-Substituted cADPR Derivatives. Journal of Medicinal Chemistry, 2008, 51, 1623-1636.	2.9	28
118	Structureâ€“Activity Relationships of C-17 Cyano-Substituted Estratrienes as Anticancer Agents. Journal of Medicinal Chemistry, 2008, 51, 1295-1308.	2.9	50
119	A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor. Clinical Cancer Research, 2008, 14, 6469-6477.	3.2	37
120	STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells. Clinical Cancer Research, 2008, 14, 597-606.	3.2	42
121	Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Molecular Cancer Therapeutics, 2008, 7, 2435-2444.	1.9	39
122	The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against Hormone-Dependent Endometrial Cancer. Endocrinology, 2008, 149, 4035-4042.	1.4	39
123	Biphenyl 2,3â€²,4,5â€²,6â€pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca 2+ responses in rat hepatocytes. FASEB Journal, 2007, 21, 1481-1491.	0.2	34
124	Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer. Oncologist, 2007, 12, 370-374.	1.9	92
125	Catalysis-associated Conformational Changes Revealed by Human CD38 Complexed with a Non-hydrolyzable Substrate Analog*. Journal of Biological Chemistry, 2007, 282, 24825-24832.	1.6	24
126	Novel Inositol Phospholipid Headgroup Surrogate Crystallized in the Pleckstrin Homology Domain of Protein Kinase BÎ±. ACS Chemical Biology, 2007, 2, 242-246.	1.6	20

#	Article	IF	Citations
127	3,17-Disubstituted 2-Alkylestra-1,3,5(10)-trien-3-ol Derivatives:â€‰ Synthesis, In Vitro and In Vivo Anticancer Activity. Journal of Medicinal Chemistry, 2007, 50, 4431-4443.	2.9	50
128	Dual Aromataseâ^'Steroid Sulfatase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 3540-3560.	2.9	75
129	Guanophostin A: Synthesis and evaluation of a high affinity agonist of the d-myo-inositol 1,4,5-trisphosphate receptor. Chemical Communications, 2006, , 2015.	2.2	12
130	Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 1,2-bridged 2â€²-phenyl-1â€²,3â€²-dioxolan-2â€²-ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5. Chemical Communications, 2006, , 2989-2991.	2.2	28
131	Unusual entry to the novel 8-halo-N1-ribosyl hypoxanthine system by degradation of a cyclic adenosine-5â€²-diphosphate ribose analogue. Chemical Communications, 2006, , 1127.	2.2	6
132	2-Substituted Estradiol Bis-sulfamates, Multitargeted Antitumor Agents:Â Synthesis, In Vitro SAR, Protein Crystallography, and In Vivo Activityâ€. Journal of Medicinal Chemistry, 2006, 49, 7683-7696.	2.9	98
133	A Systematic Study of C-Glucoside Trisphosphates as myo-Inositol Trisphosphate Receptor Ligands. Synthesis of Î²-C-Glucoside Trisphosphates Based on the Conformational Restriction Strategy. Journal of Medicinal Chemistry, 2006, 49, 1900-1909.	2.9	15
134	Synthesis of Adenophostin A Analogues Conjugating an Aromatic Group at the 5â€˜-Position as Potent IP3 Receptor Ligands. Journal of Medicinal Chemistry, 2006, 49, 5750-5758.	2.9	22
135	Modification of Estrone at the 6, 16, and 17 Positions:â€‰ Novel Potent Inhibitors of 17Î²-Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry, 2006, 49, 1325-1345.	2.9	70
136	Structural Determinants for N1/N7 Cyclization of Nicotinamide Hypoxanthine 5â€˜-Dinucleotide (NHD+) Derivatives by ADP-Ribosyl Cyclase fromAplysiacalifornica:Â Ca2+-Mobilizing Activity of 8-Substituted Cyclic Inosine 5â€˜-Diphosphoribose Analogues in T-Lymphocytes. Journal of Medicinal Chemistry, 2006, 49, 5162-5176.	2.9	34
137	Novel, potent inhibitors of 17Î²-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2006, 248, 204-207.	1.6	23
138	Cell-Permeant Small-Molecule Modulators of NAADP-Mediated Ca2+ Release. Chemistry and Biology, 2006, 13, 659-665.	6.2	16
139	scyllo â€‰nositol Pentakisphosphate as an Analogue of myo â€‰nositol 1,3,4,5,6â€‰Pentakisphosphate: Chemical Synthesis, Physicochemistry and Biological Applications. ChemBioChem, 2006, 7, 1114-1122.	1.3	23
140	3-Hydroxybenzene 1,2,4-Trisphosphate, a Novel Second Messenger Mimic and unusual Substrate for Type-I myo-Inositol 1,4,5-Trisphosphate 5-Phosphatase: Synthesis and Physicochemistry. ChemBioChem, 2006, 7, 1696-1706.	1.3	15
141	Focused Libraries of 16-Substituted Estrone Derivatives and Modified E-Ring Steroids: Inhibitors of 17ÃŸ-Hydroxysteroid Dehydrogenase Typeâ€…1. ChemMedChem, 2006, 1, 464-481.	1.6	36
142	In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy. Clinical Cancer Research, 2006, 12, 5543-5549.	3.2	62
143	Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor. Clinical Cancer Research, 2006, 12, 1585-1592.	3.2	225
144	E-Ring Modified Steroids as Novel Potent Inhibitors of 17Î²-Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry, 2005, 48, 5749-5770.	2.9	78

#	Article	IF	Citations
145	Rapid functional assays of recombinant IP3 receptors. Cell Calcium, 2005, 38, 45-51.	1.1	33
146	Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiolmono- andbis-3-O-sulphamates. International Journal of Cancer, 2005, 117, 150-159.	2.3	24
147	Crystal structure of human carbonic anhydrase II at 1.95ÂÃ... resolution in complex with 667-coumate, a novel anti-cancer agent. Biochemical Journal, 2005, 385, 715-720.	1.7	55
148	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. Cancer Research, 2005, 65, 8339-8349.	0.4	126
149	CHEMICAL SYNTHESIS OF THE NOVEL CA2+ MESSENGER NAADP. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 513-518.	0.4	6
150	First Crystal Structures of Human Carbonic Anhydrase II in Complex with Dual Aromataseâ^'Steroid Sulfatase Inhibitorsâ€,â€¡. Biochemistry, 2005, 44, 6858-6866.	1.2	42
151	A-Ring-Substituted Estrogen-3-O-sulfamates:Â Potent Multitargeted Anticancer Agents. Journal of Medicinal Chemistry, 2005, 48, 5243-5256.	2.9	68
152	Rapid Synthetic Route toward Structurally Modified Derivatives of Cyclic Adenosine 5â€˜-Diphosphate Ribose. Journal of Organic Chemistry, 2005, 70, 4810-4819.	1.7	48
153	Novel and Potent 17Î²-Hydroxysteroid Dehydrogenase Type 1 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 2759-2762.	2.9	53
154	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene, 2004, 23, 1754-1765.	2.6	89
155	Chemical Synthesis of the Second Messenger Nicotinic Acid Adenine Dinucleotide Phosphate by Total Synthesis of Nicotinamide Adenine Dinucleotide Phosphate. Angewandte Chemie - International Edition, 2004, 43, 4637-4640.	7.2	14
156	Inhibition ofin vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. International Journal of Cancer, 2004, 109, 533-540.	2.3	60
157	Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. Bioorganic and Medicinal Chemistry, 2004, 12, 2759-2772.	1.4	42
158	2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3135-3138.	1.0	35
159	2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochemical and Biophysical Research Communications, 2004, 317, 169-175.	1.0	40
160	2-O-(2-Aminoethyl)-myo-inositol 1,4,5-trisphosphate as a novel ligand for conjugation: physicochemical properties and synthesis of a new Ins(1,4,5)P3 affinity matrix. Biochemical and Biophysical Research Communications, 2004, 318, 444-452.	1.0	6
161	The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochemical and Biophysical Research Communications, 2004, 322, 217-222.	1.0	22
162	Medicinal Chemistry and Pharmacology of Cyclic ADP-Ribose. Current Molecular Medicine, 2004, 4, 303-311.	0.6	56

#	Article	IF	Citations
163	A Definitive Synthesis ofD-myo-Inositol 1,4,5,6-Tetrakisphosphate and Its EnantiomerD-myo-Inositol 3,4,5,6-Tetrakisphosphate from a Novel Butane-2,3-diacetal-Protected Inositol. Chemistry - A European Journal, 2003, 9, 6207-6214.	1.7	12
164	Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 863-865.	1.0	41
165	D-Ring Modified Estrone Derivatives as Novel Potent Inhibitors of Steroid Sulfatase. Bioorganic and Medicinal Chemistry, 2003, 11, 1685-1700.	1.4	59
166	First Dual Aromatase-Steroid Sulfatase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 3193-3196.	2.9	76
167	The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 317-325.	1.2	29
168	Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 343-349.	1.2	40
169	Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 351-358.	1.2	48
170	Synthesis and Ca2+-Mobilizing Activity of Purine-Modified Mimics of Adenophostin A:Â A Model for the Adenophostinâˆ'Ins(1,4,5)P3Receptor Interaction. Journal of Medicinal Chemistry, 2003, 46, 4860-4871.	2.9	40
171	First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist. Chemical Communications, 2003, , 1944.	2.2	33
172	Adenophostin A and ribophostin, but not inositol 1,4,5-trisphosphate or manno-adenophostin, activate the Ca2+ release-activated Ca2+ current, ICRAC, in weak intracellular Ca2+ buffer. Biochemical Journal, 2002, 361, 133.	1.7	10
173	Adenophostin A and ribophostin, but not inositol 1,4,5-trisphosphate or manno-adenophostin, activate the Ca2+ release-activated Ca2+ current, ICRAC, in weak intracellular Ca2+ buffer. Biochemical Journal, 2002, 361, 133-141.	1.7	11
174	Novel Hydrolysis-Resistant Analogues of Cyclic ADP-ribose:Â Modification of the â€œNorthernâ€•Ribose and Calcium Release Activityâ€. Biochemistry, 2002, 41, 6744-6751.	1.2	41
175	Synthesis and Biological Activity of d- and l-chiro-Inositol 2,3,4,5-Tetrakisphosphate:â€‰ Design of a Novel and Potent Inhibitor of Ins(3,4,5,6)P4 1-Kinase/Ins(1,3,4)P3 5/6-Kinase. Journal of Medicinal Chemistry, 2001, 44, 2984-2989.	2.9	17
176	Bicyclic Analogues ofd-myo-Inositol 1,4,5-Trisphosphate Related to Adenophostin A:Â Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2001, 44, 2108-2117.	2.9	22
177	Structural Determinants of Adenophostin A Activity at Inositol Trisphosphate Receptors. Molecular Pharmacology, 2001, 59, 1206-1215.	1.0	55
178	Selective recognition of inositol phosphates by subtypes of the inositol trisphosphate receptor. Biochemical Journal, 2001, 355, 59-69.	1.7	46
179	Total Synthesis of Nucleobase-Modified Adenophostin A Mimics. Chemistry - A European Journal, 2001, 7, 4937-4946.	1.7	23
180	InsP4 facilitates store-operated calcium influx by inhibition of InsP3 5-phosphatase. Nature, 2000, 408, 735-740.	13.7	99

#	Article	IF	Citations
181	myo-Inositol 1,4,6-Trisphosphorothioate andmyo-Inositol 1,3,6-Trisphosphorothioate: Partial Agonists with Very Low Intrinsic Activity at the Plateletmyo-Inositol 1,4,5-Trisphosphate Receptor. Molecular Pharmacology, 2000, 57, 595-601.	1.0	9
182	Synthesis of adenophostin A and congeners modified at glucose. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 1935-1947.	1.3	17
183	Poly(ethylene glycol)-linked dimers of d-myo-inositol 1,4,5-trisphosphate. Chemical Communications, 2000, , 983-984.	2.2	6
184	Convergent synthesis of adenophostin A analogues via a base replacement strategy. Chemical Communications, 2000, , 219-220.	2.2	17
185	Contribution of the Adenine Base to the Activity of Adenophostin A Investigated Using a Base Replacement Strategy. Journal of Medicinal Chemistry, 2000, 43, 4278-4287.	2.9	19
186	Induction of Hippocampal LTD Requires Nitric-Oxide-Stimulated PKG Activity and Ca²⁺Release From Cyclic ADP-Ribose-Sensitive Stores. Journal of Neurophysiology, 1999, 82, 1569-1576.	0.9	106
187	Acyclophostin: A Ribose-Modified Analog of Adenophostin A with High Affinity for Inositol 1,4,5-Trisphosphate Receptors and pH-Dependent Efficacy. Molecular Pharmacology, 1999, 55, 109-117.	1.0	26
188	An autoradiographic study of the distribution of binding sites for the novel Î±7-selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. European Journal of Neuroscience, 1999, 11, 2689-2696.	1.2	110
189	Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature, 1999, 398, 70-73.	13.7	316
190	Pharmacological activation of the ryanodine receptor in Jurkat T-lymphocytes. British Journal of Pharmacology, 1999, 128, 1235-1240.	2.7	14
191	Synthesis, Calcium Mobilizing, and Physicochemical Properties ofd-chiro-Inositol 1,3,4,6-Tetrakisphosphate, a Novel and Potent Ligand at thed-myo-Inositol 1,4,5-Trisphosphate Receptor. Journal of Medicinal Chemistry, 1999, 42, 1991-1998.	2.9	20
192	Selective Probes for Nicotinic Acetylcholine Receptors from Substituted AE-Bicyclic Analogs of Methyllycaconitine. ACS Symposium Series, 1998, , 194-205.	0.5	6
193	Steroidal and Nonsteroidal Sulfamates as Potent Inhibitors of Steroid Sulfatase. Journal of Medicinal Chemistry, 1998, 41, 1068-1083.	2.9	146
194	Structure-Activity Relationships of Adenophostin A and Related Molecules at the 1-D-myo-Inositol 1,4,5-Trisphosphate Receptor. ACS Symposium Series, 1998, , 158-179.	0.5	0
195	Structure-activity studies of bicyclic and tricyclic analogues of methyllycaconitine. Biochemical Society Transactions, 1997, 25, 545S-545S.	1.6	17
196	Roles for Adenosine Ribose Hydroxyl Groups in Cyclic Adenosine 5â€˜-Diphosphate Ribose-Mediated Ca2+ Release. Biochemistry, 1997, 36, 9509-9517.	1.2	56
197	Synthesis of the enantiomers of myo-inositol 1,2,4,5-tetrakisphosphate, a regioisomer of myo-inositol 1,3,4,5-tetrakisphosphate. Journal of the Chemical Society Perkin Transactions 1, 1997, , 1279-1286.	0.9	26
198	A disaccharide polyphosphate mimic of 1d-myo-inositol 1,4,5-trisphosphate. Chemical Communications, 1997, , 449-450.	2.2	20

#	Article	IF	Citations
199	Synthesis of 3-Position-Modified Analogues ofmyo-Inositol 1,4,5-Trisphosphate, Tools for Investigation of the Polyphosphoinositide Pathway of Cellular Signaling. Journal of Organic Chemistry, 1997, 62, 8335-8340.	1.7	23
200	Disaccharide Polyphosphates Based upon Adenophostin A Activate Hepatic d-myo-Inositol 1,4,5-Trisphosphate Receptors. Biochemistry, 1997, 36, 12780-12790.	1.2	71
201	1-(5-Phospho-beta-d-Ribosyl)2'-Phosphoadenosine 5'-Phosphate Cyclic Anhydride Induced Ca2+ Release in Human T-Cell Lines. FEBS Journal, 1997, 245, 411-417.	0.2	13
202	Rapid Synthesis of the Enantiomers ofmyo-Inositol-1,3,4,5-tetrakisphosphate by Direct Chiral Desymmetrization ofmyo-Inositol Orthoformate. Angewandte Chemie International Edition in English, 1997, 36, 1472-1474.	4.4	39
203	Synthesis ofd- andl-myo-Inositol 1,4,6-Trisphosphate, Regioisomers of a Ubiquitous Second Messenger. Journal of Organic Chemistry, 1996, 61, 8980-8987.	1.7	29
204	Active Site Directed Inhibition of Estrone Sulfatase by Nonsteroidal Coumarin Sulfamates. Journal of Medicinal Chemistry, 1996, 39, 1349-1351.	2.9	69
205	Long-Range 31P-31P Spin Coupling Constants in the 31P NMR Spectra of Phosphite Triesters. Phosphorus, Sulfur and Silicon and the Related Elements, 1996, 111, 71-71.	0.8	0
206	The Synthesis of Chiral Myo-Inositol Trisphosphate Analogues. Phosphorus, Sulfur and Silicon and the Related Elements, 1996, 111, 72-72.	0.8	0
207	Synthesis of Novel Polyphosphate Analogues of Inositol 1,4,5-Trisphosphate. Phosphorus, Sulfur and Silicon and the Related Elements, 1996, 111, 73-73.	0.8	0
208	Die Chemie der Inositlipidâ€vermittelten zellulÃren SignalÃ¼bertragung. Angewandte Chemie, 1995, 107, 2085-2125.	1.6	42
209	Chemistry of Inositol Lipid Mediated Cellular Signaling. Angewandte Chemie International Edition in English, 1995, 34, 1933-1972.	4.4	274
210	Inactivation of Steroid Sulfatase by an Active Site-Directed Inhibitor, Estrone-3-O-Sulfamate. Biochemistry, 1995, 34, 11508-11514.	1.2	167
211	(2-Hydroxyethyl)-Î±-D-glucopyranoside-2â€²,3,4-trisphosphate: synthesis of a second messenger mimic related to adenophostin A. Journal of the Chemical Society Chemical Communications, 1995, , 1169-1170.	2.0	15
212	Calcium release activity and metabolism of inositol 1,4,5-trisphosphate in T cells. Modulation by novel inositol 1,4,5-trisphosphate 5-phosphatase inhibitors. FEBS Journal, 1994, 222, 515-523.	0.2	6
213	The metabolism of d-myo-inositol 1,4,5-trisphosphate and d-myo-inositol 1,3,4,5-tetrakisphosphate by porcine skeletal muscle. FEBS Journal, 1994, 222, 955-964.	0.2	16
214	Modification at C2 of myo-inositol 1,4,5-trisphosphate produces inositol trisphosphates and tetrakisphosphates with potent biological activities. FEBS Journal, 1994, 223, 115-124.	0.2	44
215	Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. Journal of Medicinal Chemistry, 1994, 37, 219-221.	2.9	215
216	Synthesis of Selective Non-Ca2+ Mobilizing Inhibitors of D-myo-Inositol 1,4,5-Trisphosphate 5-Phosphatase. Journal of Medicinal Chemistry, 1994, 37, 907-912.	2.9	61

#	Article	IF	Citations
217	Design of Potent and Selective Inhibitors of myo-Inositol 1,4,5-Trisphosphate 5-Phosphatase. Biochemistry, 1994, 33, 10763-10769.	1.2	23
218	cGMP mobilizes intracellular Ca2+ in sea urchin eggs by stimulating cyclic ADP-ribose synthesis. Nature, 1993, 365, 456-459.	13.7	343
219	Synthetic Analogues of the Second Messenger D-MYOInositol 1,4,5 Trisphosphate as Receptor Agonists and Inhibitors of the Enzymes of the Polyphosphoinositide Pathway of Signal Transduction. Phosphorus, Sulfur and Silicon and the Related Elements, 1993, 76, 143-146.	0.8	2
220	Synthesis and biology of inositol polyphosphate analogues. Biochemical Society Transactions, 1992, 20, 434-442.	1.6	28
221	Total synthesis from L-quebrachitol of the D-myo-inositol 1,4,5-trisphosphate analogue, L-chiro-inositol 2,3,5-trisphosphate, a potent inositol 1,4,5-trisphosphate 5-phosphatase and 3-kinase inhibitor. Journal of the Chemical Society Chemical Communications, 1991, , 1014.	2.0	16
222	Intracellular recognition sites for inositol 1,4,5-triphosphate and inositol 1,3,4,5-tetrakisphosphate. Biochemical Society Transactions, 1991, 19, 888-893.	1.6	9
223	Phosphorothioate Analogues of D-myo-Inositol 1,4,5-Trisphosphate. ACS Symposium Series, 1991, , 186-201.	0.5	2
224	Bisphosphorylation of a vic-diol using a phosphite approach: synthesis of myo-inositol 4,5-bisphosphate. Journal of the Chemical Society Chemical Communications, 1987, , 626.	2.0	18
225	Stereochemical evidence for a phosphorylpyridinium intermediate in the iodine-mediated desulphurisation of a phosphorothioate diester. Journal of the Chemical Society Chemical Communications, 1985, , 800.	2.0	9